Lilly, BI resubmit diabetes medication

Share this article:

Lilly and Boehringer Ingelheim are resubmitting their experimental SGLT2 diabetes medication empagliflozen to the FDA.

“We are very pleased to move forward . . . following a FDA inspection of the Boehringer Ingelheim facility,” BI president and CEO Paul Fonteyne said in a statement Tuesday, referring to the CRL that halted the FDA's review.

The European Commission greenlighted the diabetes medication, known as Jardiance, in May.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.